Probiotics: From clinical trial to health claims success

By Stephen Daniells

- Last updated on GMT

As a raft of non-positive opinions on probiotics floats down the health claims river, questions have been asked of the efficacy of the beneficial bacteria. Two experts discuss where we stand and how to get the good ship Probiotic back on course.

Chr Hansen's Svend Laulund and Joerg Gruenwald, president of CRO, Analyze & Realize talk to Stephen Daniells about what the recent EFSA rejections really mean for probiotics.

Laulund and Gruenwald also discuss how to fulfill EFSA's criteria and achieve a positive health claim. A good place to start would be correct characterisation of the strains, quickly followed by conducting studies in healthy populations.

These issues and more will be discussed at the upcoming NutraIngredients Health Claims 2010 conference in Brussels. Danone will discuss its response to the health claims process along with Provexis and others on Thursday, 10th December. Others include Unilever, analyze&realize, Cantox, academics, industry groups, lawyers and market experts. For more information and to register, please click here​.

Related news

Show more

Related products

show more

BB536 for optimal Gut health and beyond

BB536 for optimal Gut health and beyond

Content provided by Morinaga Milk Industry Co., Ltd. | 03-Oct-2024 | White Paper

Among the various probiotics strains available, Bifidobacterium longum BB536 stands out due to its well-documented safety, efficacy, and regulatory approvals....

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

Related suppliers

Follow us

Products

View more

Webinars